Letrozole-induced inflammatory arthritis and tendinopathy in pediatric rheumatology setting

Int J Rheum Dis. 2023 Nov;26(11):2314-2316. doi: 10.1111/1756-185X.14748. Epub 2023 May 23.

Abstract

Musculoskeletal symptoms associated with the use of aromatase inhibitors are a well-known side effect of these drugs and are more prevalent in postmenopausal women. Aromatase inhibitor-associated symptoms are not overt inflammatory processes so are described as arthralgia syndrome. In contrast, aromatase inhibitor-associated inflammatory conditions such as myopathies, vasculitis, and rheumatoid arthritis were also reported. To our knowledge, inflammatory arthritis or tendinopathy associated with aromatase inhibitors were not reported in children despite their increased off-label use in the pediatric setting. Herein, we report a girl with inflammatory arthritis and tendinopathy associated with letrozole treatment.

Keywords: enthesitis-related arthritis; female; inflammatory arthritis; letrozole; tendinopathy.

Publication types

  • Case Reports

MeSH terms

  • Aromatase Inhibitors / adverse effects
  • Arthritis, Rheumatoid* / drug therapy
  • Breast Neoplasms* / drug therapy
  • Child
  • Female
  • Humans
  • Letrozole / adverse effects
  • Musculoskeletal Diseases* / drug therapy
  • Rheumatology*
  • Tendinopathy* / chemically induced
  • Tendinopathy* / diagnosis

Substances

  • Letrozole
  • Aromatase Inhibitors